Solara Active Pharma Sciences Limited manufactures, produces, processes, formulates, sells, imports, exports, merchandises, distributes, trades in, and deals in active pharmaceutical ingredients (API) in India, Asia Pacific, Europe, North America, South America, and internationally. It offers APIs for amyotrophic lateral sclerosis, anesthetics, anthelmintic, anti hyperlipidemic, anti-arrhythmic ag...
Solara Active Pharma Sciences reported revenue of 12.41 billion INR for fiscal year 2025, up 0.2% from fiscal year 2024, and net income of 5.40 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 3.49 billion INR, up 16.2% from a year before. Its market capitalization was 31.09 billion INR as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended March 31, 2025; market data as of October 9, 2026.
No profile data available.